Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod effects on gastric sensitivity in heartburn and dyspepsia
NCT00171457Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tegaserod in Functional heartburn (FH) and dyspepsia (2 arms), sponsored by Novartis. Primary endpoint: Modulation of gastric sensitivity to mechanical distention of the stomach. Started Apr 2005; status: completed.
02
Drugs
tegaserod
03
Conditions
Functional heartburn (FH)dyspepsia
Beyond the preview
Go deeper on NCT00171457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171457.